Among patients with nonalcoholic fatty liver disease (NAFLD), the use of statins is associated with reduced cancer-related mortality, according to a study published in the Journal of Clinical Gastroenterology.
Cardiovascular disease (CVD) is common among patients with NAFLD and is the leading cause of morbidity and mortality. However, rates of malignancy-related mortality have increased dramatically in recent years. While epidemiologic studies have suggested a possible association between statin use and a decreased risk for various malignancies, this association remains debatable given the observational nature of the available evidence and the risk for confounders.